Lansforsakringar Fondforvaltning AB publ Increases Position in Edwards Lifesciences Corporation $EW

Lansforsakringar Fondforvaltning AB publ boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 273,323 shares of the medical research company’s stock after acquiring an additional 10,747 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Edwards Lifesciences were worth $21,256,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $266,000. Strategic Blueprint LLC lifted its stake in Edwards Lifesciences by 66.0% in the 2nd quarter. Strategic Blueprint LLC now owns 6,028 shares of the medical research company’s stock valued at $471,000 after buying an additional 2,397 shares in the last quarter. Asset Management One Co. Ltd. boosted its stake in Edwards Lifesciences by 0.9% during the 2nd quarter. Asset Management One Co. Ltd. now owns 252,425 shares of the medical research company’s stock worth $19,742,000 after purchasing an additional 2,336 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $106,000. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in shares of Edwards Lifesciences by 1.3% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,375,336 shares of the medical research company’s stock valued at $107,565,000 after buying an additional 17,937 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the transaction, the vice president directly owned 31,870 shares in the company, valued at approximately $2,729,984.20. The trade was a 26.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 43,804 shares of company stock valued at $3,699,082. Corporate insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on EW shares. BTIG Research reiterated a “buy” rating and set a $103.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Evercore reaffirmed an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 5th. The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price objective (down previously from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Mizuho lifted their price target on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Trading Up 1.2%

NYSE:EW opened at $79.88 on Monday. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The stock’s 50 day simple moving average is $82.80 and its 200-day simple moving average is $81.05. The firm has a market cap of $46.35 billion, a P/E ratio of 43.65, a PEG ratio of 2.08 and a beta of 0.94.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.